Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

Indians have long awaited the global sensation Ozempic and, now, they finally have access to Eli Lilly’s Mounjaro— an advanced alternative that offers similar benefits for weight loss and diabetes ...

While Jasmine didn’t suffer majorly with side effects, she did claim that Mounjaro had a very unexpected impact on her menstrual cycle. Mounjaro, regarded by some as the King Kong of weight ...

Recently, the weight loss drug introduced by Eli Lilly, Mounjaro, has been launched in India sparking a debate among health experts With the launch of the weight loss drug introduced by Eli Lilly, ...

US-based pharmaceutical giant Eli Lilly recently launched its weight loss drug Mounjaro in India. Tirzepatide is the generic name, the active pharmaceutical ingredient. The medicine, which has ...

Now that one of the most advanced weight loss drugs, Mounjaro, is to be sold in India by US pharma major Eli Lilly, there’s curiosity about its long-term effects and whether the lost weight comes back ...

Mounjaro is used to treat type 2 diabetes and obesity Credit: Getty Posting on TikTok, the mum-of-two, who is from the UK, shared a short clip showing off her new figure, leaving many totally stunned.

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding weight loss alongside diabetes treatment The Ozempic craze is not yet over ...

Eli Lilly introduced Mounjaro, also known as Zepbound, in India for the management of obesity and diabetes. JM Financial is bullish on the weight-loss drug's success in India, citing its price ...

Sunny Hostin opened up about using weight-loss drug Mounjaro (Getty Images) NEW YORK CITY, NEW YORK: Sunny Hostin has candidly discussed her experience with the weight-loss drug Mounjaro, which helped ...

Weight-loss drugs are trending, with Ozempic and the latest launch, Mounjaro—considered a likely equivalent to Ozempic—gaining popularity. But will these new drugs influence consumer buying patterns?